Alnylam Pharmaceuticals, Inc. Earnings

Alnylam Pharmaceuticals, Inc.’s revenue jumped 149.35% since last year same period to $1249.03Mn in the Q3 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 61.44% jump in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit jumped 325.05% since last year same period to $251.08Mn in the Q3 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 478.84% jump in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin jumped 190.25% since last year same period to 20.1% in the Q3 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 334.67% jump in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.24 - a -13.89% fall from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 1.24.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2025. This indicates that the Alnylam Pharmaceuticals, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.